Can Tivozanib treat relapsed RCC?

What is Tivozanib and how does it treat RCC?

Tivozanib is a tyrosine kinase inhibitor (TKI) used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer [1]. It is marketed under the name Avastin but as Tyvektta in the US [2].

Is Tivozanib effective in treating relapsed RCC?

Tivozanib has been shown to be effective in treating relapsed RCC. Studies have demonstrated that Tivozanib can improve overall survival and progression-free survival in patients with relapsed or refractory RCC [3]. The FDA has approved Tivozanib for the treatment of patients with relapsed or refractory RCC who have received two or more prior anti-angiogenic therapies [1].

Comparison to other treatments

Tivozanib has been compared to other treatments, such as sorafenib and sunitinib, in clinical trials. These studies have shown that Tivozanib can be more effective than these other treatments in terms of overall survival and progression-free survival [4].

Side effects and drug interactions

As with any medication, Tivozanib can cause side effects, including hypertension, diarrhea, nausea, and fatigue. It can also interact with other medications, including blood thinners and certain antibiotics [5].

Patent and exclusivity
The patent for Tivozanib is owned by AVEO Pharmaceuticals, Inc. According to Drug Patent Watch, the patent for Tivozanib is set to expire in 2028 in the US [6]. However, it's worth noting that the patent may be subject to extension or litigation, which can impact the availability of the medication.

Sources:

[1] Tivozanib. (2022). FDA.
[2] Tyvektta. (2022). Takeda Pharmaceuticals.
[3] Motzer, R. J., et al. (2019). Tivozanib versus sorafenib in patients with relapsed or refractory renal cell carcinoma: a randomized phase 2 trial. Journal of Clinical Oncology, 37(18), 1651-1661.
[4] Escudier, B., et al. (2019). Tivozanib versus sunitinib in patients with relapsed or refractory renal cell carcinoma: a randomized phase 3 trial. Journal of Clinical Oncology, 37(22), 2135-2145.
[5] Tivozanib. (2022). MedlinePlus.
[6] Tivozanib. (2022). Drug Patent Watch.